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ABSTRACT: HIV drug resistance still represents a crucial problem in antiretroviral therapy. We 
report a case of a naive patient, harboring a CRF11-cpx virus, which showed drug resistance 
mutations in the reverse transcriptase. Drug resistance genotyping test was performed 
for pol (protease, reverse transcriptase, and integrase) and V3 regions. The initial clinical 
parameters results showed a 4 logs level of HIV-RNA (12,090 cp/mL) and a very low CD4+ cell 
count (35 cells/µL). We designed an initial HAART regimen including 3TC+ABC+DRV/r. The 
virus resulted highly resistant to all NRTIs and NNRTIs except to ABC, TDF, and EFV and 
susceptible to all PIs and INIs. A salvage regimen including RAL+DRV/r was started. Ten months 
after, the immuno-virological status shows CD4+ 142/µL and HIV-RNA <37 cp/mL.  Our results 
demonstrate the effectiveness of a treatment combination that includes RAL+DRV/r in a patient 
infected with a complex X4-tropic CRF11-cpx virus. 
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Human Immunodeficiency virus type 1 (HIV-1) is characterized  by a high genetic variability 
caused mainly by errors of the reverse transcriptase (RT)  during high  rates of virus replication . (1) 
Based on phylogenetic analysis of gene sequences, HIV-1 strains were classified into four distinct 
groups: M (Major), O (Outlier), N (non-M, non-O) and P. Group M strains represents the majority 
of  HIV infections in the global pandemic and are divided into nine subtypes (A-D, F-H, J and K), 2 
sets of subtypes (A1, A2, A3, A4 and F1 and F2), circulating recombinant forms (CRFs)  and a 
single recombinant (URFs), which  results from the recombination of two or more subtypes. (2) 
In the context of African countries, HIV-1 group O (HIV-1O) virus is one of the most frequent 4 
groups of HIV-1, which includes also groups M, N e P. Most of the identified cases of HIV-1O 
worldwide have been identified in Cameroon and Central America with a percentage of 
approximately 1% of all  HIV-1 infections. Other cities in Africa and in Europe have reported the 
presence of HIV-10 mostly  in low proportions. HIV-1O variants are genotypically divergent from 
HIV-1 group M viruses and a significant genetic variation, connected to important consequences in  
diagnosis and monitoring, is observed within  group O. (3) 
Group M is responsible for the pandemic and can be divided into subtypes, subsubtypes, and 
circulating recombinant forms (CRFs). (4) Specific distributions of the various subtypes are seen in 
the different continents and the greatest genetic diversity of HIV-1 has been found in Africa. (5,6) A 
mixture of  HIV-1 variants results in an increasing likelihood of generating new recombinant 
viruses. Differences related to efficiency of antiretroviral drugs and diagnostic assays have been 
reported among the various HIV-1 variants and preliminary data suggest differences in pathogenesis 
and transmissibility. (5,6)  Therefore, it remains important to track the molecular epidemiology of 
HIV-1 and to genetically characterize prevalent HIV-1 strains. 
So far, six genomes of CRF11-cpx have been reported: GR17 (AF179368) by Paraskevis et al. in 
2000; MP818 (AJ291718), MP1298 (AJ291719), and MP1307 (AJ291720) by Montavon et al. in 
2002; and 96CM4496 (AF492623) and 95CM1816 (AF492624) by Wilbe et al. in 2002. In the 
nef/LTR region, both the A and E segments appear to be derived from CRF01_AE, while the other 
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A segments are not. The segments labeled U were regions where the sequence was equidistant 
between G and J. (7,8,9) Thereby, we report the case of a HIV-1-infected naive patient, harboring a 
CRF-11cpx virus, which showed several drug resistance mutations in the RT. 
Our patient, a 41-year-old men, was evaluated from 2007 to 2010 in Bangui, Central African 
Repubblic, where he performed several HIV-1-Ab tests with negative results, with the exception of 
a positive test in 2007,which was not confirmed at later time points.  
RNA was extracted from plasma using QIAmp Viral RNA Mini Kit (Qiagen, Inc., Valencia, CA) 
according to the manufacturer’s protocol.  
EDTA whole blood was collected to perform CD4 T cell count. The viral load was assessed using 
the kPCR Real Time-PCR method (Siemens Healthcare Diagnostic Inc., Deerfield, IL, USA) with a 
cut-off of 37 cp/ml. Drug resistance genotyping test was performed on plasma samples by means of 
the TRUGENE HIV-1 kit (Siemens Healthcare Diagnostic Inc., Deerfield, IL, USA) for pol 
(protease, reverse transcriptase and integrase). V3 regions were sequenced according to a protocol 
used in the OSCAR study, which was adapted for the Siemens system. (10) 
To determine the subtype of 6337257_pt, the pol sequence was aligned with HIV-1 reference 
sequences the CLUSTAL W method (MegAlign, Lasergene v. 7.2.1, DNAstar, Inc., Madison, WI). 
Three reference sequences of subtype CFR11-cpx were included in the alignment. Gaps were 
stripped from the alignment using BioEdit (v.7.0.4.1, T.A. Hall, 1999, North Carolina State 
University, Raleigh, NC). Phylogenetic analysis was performed using PHYLIP (v. 3.67). 
Evolutionary distances were estimated with DNADIST (Kimura two-parameter method) and 
phylogenetic relationship were determined by NEIGHBOR (neighbour-joining method). 
Reproducibility of trees was evaluated using SEQBOOT (1000 replicates) and CONSENSE. Trees 
were constructed using FigTree. Programs were run with default parameters. 
 
The patient was tested for HIV-1 Ab Elisa and Western Blot in March 2012 in Milan with a positive 
result. 
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In regards to the presentation of this patient, in April 2012 the initial clinical parameters showed a 4 
logs level of HIV-RNA (12,090 copies/mL), a very low CD4+ cell count (35 cells/µL; 2.1%) and an 
A3 CDC clinical stage. We designed an initial HAART regimen including was abacavir 
(ABC)/lamivudine (3TC), darunavir (800 mg QD) and booster ritonavir (DRV/r) before the drug 
resistance results were available, due to the serious immunological status. 
The resistance report showed a number of drug resistance mutations and possible resistance 
mutations to Nucleoside and Nucleotide RT Inhibitors and Non Nucleoside RT Inhibitors except to 
ABC, tenofovir (TDF), and efavirenz (EFV), which showed an intermediate resistance, and 
susceptible to all protease inhibitors (PIs) and integrase inhibitors (INIs), according to the Stanford 
algorithm. This mutation pattern included  M41L, A62V, T69N, K70R, V75I/S, Y181I, M184V, 
T215F/S in the RT region, no relevant mutations were detected in the protease region according to 
the Stanford algortithm. The Geno2Pheno analysis of the gp120 V3 region showed a CXCR4 virus 
(FPR: 5.3).   (Fig1) 
After considering these results, the antiretroviral therapy was changed:  ABC/3TC were substituted 
with raltegravir (RAL) 400 mg BID. The new treatment was accompanied by monthly clinical 
assessments and quarterly biological monitoring including CD4 T cells count and HIV-RNA 
quantification. 
In June 2012, he was tested for HBsAg with a positive result, up to 125,000 copies/ml (68 
CD4cells/µL; 3.5%) . In July 2012, he had a viral load referred as HBV-DNA equal to 720,000 
copies/mL (82 CD4cells/ µL; 3.0%) and tenofovir was added to the other antiretrovirals.In 
September 2012, the HBV-DNA decreased to 139,445 copies/mL (114 cells/µL; 4.4%). In 
November 2012, the HBsAg load was 65079,59 copies/mL and HBV-DNA was 19,604 copies/mL 
(154 CD4 cells/µL; 6.1%). In February 2013, HBV-DNA was 627 copies/mL (142 CD4cells/µL; 
8.4%).  
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Thus, thirteen months after starting the salvage regimen the patient’s clinical condition has been 
excellent without side effects; his current immuno-virological status shows CD4 302/µL (10.9%) 
and HIV-RNA <37 cp/mL.   
For phylogenetics analysis, the 2010 HIV-1/SIVcpz complete genome alignment was downloaded 
from the Los Alamos HIV sequence database. (2) The alignment was modified by restricting it to 
group M subtypes and CRF 11cpx.  Patient’s sequence was added to this alignment and adjusted 
manually, then gap-stripped using BioEdit. Phylogenetic analysis showed that patient’s sequence 
branched with the CFR11-cpx with a bootstrap value of  99%.  Horizontal branch lengths were 
drawn to scale with the bar at the bottom indicating 0.02 nucleotide substitution per site.  (Fig. 2) 
Bootscan analysis using SimPlot (v. 3.5, S.C. Ray, John Hopkins University, Baltimore, MD) was 
performed to compare the overall genomic composition of patient’s sequence to consensus 
sequences for group M reference strains (A1, A2, A3, A4, B, C, D, F1, F2, G, H, J, and K) and the 
three consensus sequences of CRF11-cpx. The patient’s sequence branched with CRF11cpx 
consensus sequences.  
 
Our results indicate that the salvage treatment was successful in this patient despite his background 
of resistance to almost all NRTIs and NNRTIs.  
As for the DRV/r plus RAL combination, Akil Jackson et al. carried out a study which analyzed 
DRV/r and RAL plasma and intracellular concentrations in HIV-infected individuals during co-
administration. In this study, HIV-infected patients on antiretroviral therapy received RAL 400 mg 
twice daily for 21 days; DRV/r 800/100 mg once daily was added for 14 days and patients were 
randomized to continue RAL twice daily or to switch to 800 mg once daily, then they all stopped 
RAL intake and continued DRV/r once daily for 14 days. Drug concentrations in plasma and 
peripheral blood mononuclear cells were measured. No remarkable interactions 
between DRV/r and RAL in plasma or cells were seen. Raltegravir intracellular concentrations were 
assessed for the once-daily 800 mg dose for the first time. (11) More recently, once-daily DRV/r 
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has received approval in treatment-naïve patients and represents an excellent option for first-line 
therapy. (12) 
In regards to the addition of TDF, its administration  in HIV/HBV-coinfected patients for up to 6 
years led to a significant decrease in HBsAg in the HBeAg-positive population. Early HBsAg 
kinetics during treatment were predictive of HBsAg seroclearance and correlated with an increased 
CD4 cell count, underlining the importance of immune restoration in HBV clearance. (13) 
Our patient’s was from the Central African Republic. First data on HIV-1 resistance mutations to 
antiretroviral drugs in Central African Republic was performed by Moussa et al. In this study, they 
present sequence data of non-B HIV-1 isolates obtained in 2008-2009 from Central African patients 
failing  a stavudine (d4T)/zidovudine (AZT)-3TC- nevirapine (NVP)/EFV regimen, together with 
two patients at failure of a regimen, including a protease inhibitor (indinavir, IDV) The resistance 
mutations observed are those which are expected in HIV-1 subtype B. These data confirm the high 
diversity of HIV-1, which reflects the different non-B subtypes/CRFs and the various drugs used 
and do not provide evidence of new mutation profiles compared to subtype B. (14) 
Notwithstanding the difficult virological presentation, complicated by HBV co-infection, we 
designed an effective treatment combination that included RAL+DRV/r+TDF with the aid of 
precise molecular tools. Our patient presented  a sustained immunological and virological response 
overcoming difficulties posed by  a complex CXCR4-tropic CRF11-cpx virus.  
 
ACCESSION NUMBER: the sequences described in this paper were submitted to the GenBank 
Nucleotide Sequence Database under accession number KF279645, KF381390, KF381391, and 
KF381392. 
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Fig.1 Profile of Drug Resistance Mutations at Salvage Therapy Initiation.  
 
 
Fig. 2 Neighbour joining tree of 2010 HIV-1/SIVcpz complete genome and the patient’s sequence 
(pt_6337257) that are marked. Bootstrap support is shown for key nodes. Horizontal branch lengths 
are drawn to scale with the bar at the bottom indicating 0.02 nucleotide substitution per site.  
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ABSTRACT: HIV drug resistance still represents a crucial problem in antiretroviral therapy. We 
report a case of a naive patient, harboring a CRF11-cpx virus, which showed drug resistance 
mutations in the reverse transcriptase. Drug resistance genotyping test was performed 
for pol (protease, reverse transcriptase, and integrase) and V3 regions. The initial clinical 
parameters results showed a 4 logs level of HIV-RNA (12,090 cp/mL) and a very low CD4+ cell 
count (35 cells/µL). We designed an initial HAART regimen including 3TC+ABC+DRV/r. The 
virus resulted highly resistant to all NRTIs and NNRTIs except to ABC, TDF, and EFV and 
susceptible to all PIs and INIs. A salvage regimen including RAL+DRV/r was started. Ten months 
after, the immuno-virological status shows CD4+ 142/µL and HIV-RNA <37 cp/mL.  Our results 
demonstrate the effectiveness of a treatment combination that includes RAL+DRV/r in a patient 
infected with a complex X4-tropic CRF11-cpx virus. 
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Human Immunodeficiency virus type 1 (HIV-1) is characterized  by a high genetic variability 
caused mainly by errors of the reverse transcriptase (RT)  during high  rates of virus replication . (1) 
Based on phylogenetic analysis of gene sequences, HIV-1 strains were classified into four distinct 
groups: M (Major), O (Outlier), N (non-M, non-O) and P. Group M strains represents the majority 
of  HIV infections in the global pandemic and are divided into nine subtypes (A-D, F-H, J and K), 2 
sets of subtypes (A1, A2, A3, A4 and F1 and F2), circulating recombinant forms (CRFs)  and a 
single recombinant (URFs), which  results from the recombination of two or more subtypes. (2) 
In the context of African countries, HIV-1 group O (HIV-1O) virus is one of the most frequent 4 
groups of HIV-1, which includes also groups M, N e P. Most of the identified cases of HIV-1O 
worldwide have been identified in Cameroon and Central America with a percentage of 
approximately 1% of all  HIV-1 infections. Other cities in Africa and in Europe have reported the 
presence of HIV-10 mostly  in low proportions. HIV-1O variants are genotypically divergent from 
HIV-1 group M viruses and a significant genetic variation, connected to important consequences in  
diagnosis and monitoring, is observed within  group O. (3) 
Group M is responsible for the pandemic and can be divided into subtypes, subsubtypes, and 
circulating recombinant forms (CRFs). (4) Specific distributions of the various subtypes are seen in 
the different continents and the greatest genetic diversity of HIV-1 has been found in Africa. (5,6) A 
mixture of  HIV-1 variants results in an increasing likelihood of generating new recombinant 
viruses. Differences related to efficiency of antiretroviral drugs and diagnostic assays have been 
reported among the various HIV-1 variants and preliminary data suggest differences in pathogenesis 
and transmissibility. (5,6)  Therefore, it remains important to track the molecular epidemiology of 
HIV-1 and to genetically characterize prevalent HIV-1 strains. 
So far, six genomes of CRF11-cpx have been reported: GR17 (AF179368) by Paraskevis et al. in 
2000; MP818 (AJ291718), MP1298 (AJ291719), and MP1307 (AJ291720) by Montavon et al. in 
2002; and 96CM4496 (AF492623) and 95CM1816 (AF492624) by Wilbe et al. in 2002. In the 
nef/LTR region, both the A and E segments appear to be derived from CRF01_AE, while the other 
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A segments are not. The segments labeled U were regions where the sequence was equidistant 
between G and J. (7,8,9) Thereby, we report the case of a HIV-1-infected naive patient, harboring a 
CRF-11cpx virus, which showed several drug resistance mutations in the RT. 
Our patient, a 41-year-old men, was evaluated from 2007 to 2010 in Bangui, Central African 
Repubblic, where he was tested with performed several HIV-1-Ab tests with negative results, with 
the exception of a positive test in 2007,which was not confirmed at later time points and for HIV-1 
Ab Elisa and Western Blot in March 2012 in Milan with a positive result..  
RNA was extracted from plasma using QIAmp Viral RNA Mini Kit (Qiagen, Inc., Valencia, CA) 
according to the manufacturer’s protocol.  
EDTA whole blood was collected to perform CD4 T cell count. The viral load was assessed using 
the kPCR Real Time-PCR method (Siemens Healthcare Diagnostic Inc., Deerfield, IL, USA) with a 
cut-off of 37 cp/ml. Drug resistance genotyping test was performed on plasma samples by means of 
the TRUGENE HIV-1 kit (Siemens Healthcare Diagnostic Inc., Deerfield, IL, USA) for pol 
(protease, reverse transcriptase and integrase). V3 regions were sequenced according to a protocol 
used in the OSCAR study, which was adapted for the Siemens system. (10) 
To determine the subtype of 6337257_pt, the pol sequence was aligned with HIV-1 reference 
sequences the CLUSTAL W method (MegAlign, Lasergene v. 7.2.1, DNAstar, Inc., Madison, WI). 
Three reference sequences of subtype CFR11-cpx were included in the alignment. Gaps were 
stripped from the alignment using BioEdit (v.7.0.4.1, T.A. Hall, 1999, North Carolina State 
University, Raleigh, NC). Phylogenetic analysis was performed using PHYLIP (v. 3.67). 
Evolutionary distances were estimated with DNADIST (Kimura two-parameter method) and 
phylogenetic relationship were determined by NEIGHBOR (neighbour-joining method). 
Reproducibility of trees was evaluated using SEQBOOT (1000 replicates) and CONSENSE. Trees 
were constructed using FigTree. Programs were run with default parameters. 
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The patient was tested for HIV-1 Ab Elisa and Western Blot in March 2012 in Milan with a positive 
result. 
In regards to the presentation of this patient, in April 2012 the initial clinical parameters showed a 4 
logs level of HIV-RNA (12,090 copies/mL), a very low CD4+ cell count (35 cells/µL; 2.1%) and an 
A3 CDC clinical stage. We designed an initial HAART regimen including was abacavir 
(ABC)/lamivudine (3TC), darunavir (800 mg QD) and booster ritonavir (DRV/r) before the drug 
resistance results were available, due to the serious immunological status. 
The resistance report showed a number of drug resistance mutations and possible resistance 
mutations to Nucleoside and Nucleotide RT Inhibitors and Non Nucleoside RT Inhibitors except to 
ABC, tenofovir (TDF), and efavirenz (EFV), which showed an intermediate resistance, and 
susceptible to all protease inhibitors (PIs) and integrase inhibitors (INIs), according to the Stanford 
algorithm. This mutation pattern included  M41L, A62V, T69N, K70R, V75I/S, Y181I, M184V, 
T215F/S in the RT region, no relevant mutations were detected in the protease region according to 
the Stanford algortithm. The Geno2Pheno analysis of the gp120 V3 region showed a CXCR4 virus 
(FPR: 5.3).   (Fig1) 
After considering these results, the antiretroviral therapy was changed:  ABC/3TC were substituted 
with raltegravir (RAL) 400 mg BID. The new treatment was accompanied by monthly clinical 
assessments and quarterly biological monitoring including CD4 T cells count and HIV-RNA 
quantification. 
In June 2012, he was tested for HBsAg with a positive result, up to 125,000 copies/ml (68 
CD4cells/µL; 3.5%) . In July 2012, he had a viral load referred as HBV-DNA equal to 720,000 
copies/mL (82 CD4cells/ µL; 3.0%) and tenofovir was added to the other antiretrovirals. In 
September 2012, the HBV-DNA decreased to 139,445 copies/mL (114 cells/µL; 4.4%). In 
November 2012, the HBsAg load was 65079,59 copies/mL and HBV-DNA was 19,604 copies/mL 
(154 CD4 cells/µL; 6.1%). In February 2013, HBV-DNA was 627 copies/mL (142 CD4cells/µL; 
8.4%).  
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Thus, thirteen months after starting the salvage regimen the patient’s clinical condition has been 
excellent without side effects; his current immuno-virological status shows CD4 302/µL (10.9%) 
and HIV-RNA <37 cp/mL.   
For phylogenetics analysis, the pol gene 2010 HIV-1/SIVcpz complete genomesubtype reference 
alignment was downloaded from the Los Alamos HIV sequence database. (2) The alignment was 
modified by restricting it to group M subtypes and CRF 11cpx.  Patient’s sequence was added to 
this alignment and adjusted manually, then gap-stripped using BioEdit. Phylogenetic analysis 
showed that patient’s sequence branched with the CFR11-cpx with a bootstrap value of  99%.  
Horizontal branch lengths were drawn to scale with the bar at the bottom indicating 0.02 nucleotide 
substitution per site.  (Fig. 2) 
Bootscan analysis using SimPlot (v. 3.5, S.C. Ray, John Hopkins University, Baltimore, MD) was 
performed to compare the overall genomic composition of patient’s sequence to consensus 
sequences for group M reference strains (A1, A2, A3, A4, B, C, D, F1, F2, G, H, J, and K) and the 
three consensus sequences of CRF11-cpx. The patient’s sequence branched with CRF11cpx 
consensus sequences.  
 
Our results indicate that the salvage treatment was successful in this patient despite his background 
of resistance to almost all NRTIs and NNRTIs.  
As for the DRV/r plus RAL combination, Akil Jackson et al. carried out a study which analyzed 
DRV/r and RAL plasma and intracellular concentrations in HIV-infected individuals during co-
administration. In this study, HIV-infected patients on antiretroviral therapy received RAL 400 mg 
twice daily for 21 days; DRV/r 800/100 mg once daily was added for 14 days and patients were 
randomized to continue RAL twice daily or to switch to 800 mg once daily, then they all stopped 
RAL intake and continued DRV/r once daily for 14 days. Drug concentrations in plasma and 
peripheral blood mononuclear cells were measured. No remarkable interactions 
between DRV/r and RAL in plasma or cells were seen. Raltegravir intracellular concentrations were 
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assessed for the once-daily 800 mg dose for the first time. (11) More recently, once-daily DRV/r 
has received approval in treatment-naïve patients and represents an excellent option for first-line 
therapy. (12) 
In regards to the addition of TDF, its administration  in HIV/HBV-coinfected patients for up to 6 
years led to a significant decrease in HBsAg in the HBeAg-positive population. Early HBsAg 
kinetics during treatment were predictive of HBsAg seroclearance and correlated with an increased 
CD4 cell count, underlining the importance of immune restoration in HBV clearance. (13) 
Our patient’s was from the Central African Republic. First data on HIV-1 resistance mutations to 
antiretroviral drugs in Central African Republic was performed by Moussa et al. In this study, they 
present sequence data of non-B HIV-1 isolates obtained in 2008-2009 from Central African patients 
failing  a stavudine (d4T)/zidovudine (AZT)-3TC- nevirapine (NVP)/EFV regimen, together with 
two patients at failure of a regimen, including a protease inhibitor (indinavir, IDV) The resistance 
mutations observed are those which are expected in HIV-1 subtype B. These data confirm the high 
diversity of HIV-1, which reflects the different non-B subtypes/CRFs and the various drugs used 
and do not provide evidence of new mutation profiles compared to subtype B. (14) 
Notwithstanding the difficult virological presentation, complicated by HBV co-infection, we 
designed an effective treatment combination that included RAL+DRV/r+TDF with the aid of 
precise molecular tools. Our patient presented  a sustained immunol gical and virological response 
overcoming difficulties posed by  a complex CXCR4-tropic CRF11-cpx virus.  
 
ACCESSION NUMBER: the sequences described in this paper were submitted to the GenBank 
Nucleotide Sequence Database under accession number KF279645, KF381390, KF381391, and 
KF381392. 
 
Authors disclosure statement: No competing financial interest exist. 
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Dear Editor, 
we submit a revised version of the manuscript entitled “FAVORABLE THERAPEUTIC 
RESPONSE WITH AN ANTIRETROVIRAL SALVAGE REGIMEN IN A HIV-1 POSITIVE 
SUBJECT INFECTED WITH A CRF11-CPX VIRUS”. We have responded to the queries posed by 
the reviewer as described in the e-mail of October 28.  
 
 
1)  It is not clear how the authors concluded that the majority of virions in this patient use the 
CXCR4 coreceptor.  Most HIV-1 isolates use the CCR5 coreceptor, and there is some 
correlation between V3 sequence and coreceptor use, but the sequence with accession 
number KF381391 has so many "R", "Y" and other ambiguity codes in it, that it is not 
possible for the Geno2Pheno or similar programs to make an accurate prediction of 
coreceptor use. 
To determine the virus tropism we used a FPR significance level of 10%, according to the 
Recommendations from the European Consensus Group on clinical management of HIV-1 
tropism testing (LPR Vandekerckhove et al.; European guidelines on the clinical 
management of HIV-1 tropism testing; The Lancet Infectious Diseases, Volume 11, Issue 5, 
Pages 394 - 407, May 2011), while the reviewer used a FPR cut-off of 1%: for this reason 
we concluded that patient harbours a CXCR4-tropic virus. Moreover, the reviewer changed 
the sequence with accession number KF381391:  all ambiguity codes were substituted with 
N code (as reported in the geno2pheno report attached by the reviewers). These changes 
resulted in several aminoacids substitutions, that affected and worsened the geno2pheno 
interpretation. Ambiguity are usually present in HIV sequences (especially in the gp120 
hypervariable domains), owing to the high heterogeneity and variability of viral population. 
In our opinion, we would not modify the referenced sequence, thus  introducing aminoacids 
changes not present in our original sequence and indeed in the sample (i.e.: in our sequence 
the 11th codon is AGY, coding for Ser for both AGT and AGC; in the reviewers sequence at 
the same position it is reported a AGN codon, that could encode Ser for AGT and AGC and 
Arg for AGA and AGG). 
 
2)  The drug resistance profile reported for this patient does not match the results I get using 
the Stanford drug resistance database 
( http://sierra2.stanford.edu/sierra/servlet/JSierra?action=sequenceInput ): 
 
KF381391 result: 
NRTI Resistance Mutations:  M41LM, A62AV, T69N, K70KR, V75GISV, M184V, 
T215FIST 
NNRTI Resistance Mutations:  Y181I 
Other Mutations:  K49KR, K122E, D123N, S162CS, K173T, Q174K, D177E, T200EQ, 
I202V, Q207E, R211K, E224D, T240R, P243A, V245Q 
Nucleoside RTI 
Page 26 of 28
Mary Ann Liebert Inc., 140 Huguenot Street, New Rochelle, NY 10801
AIDS Research and Human Retroviruses
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only; Not for Distribution
lamivudine (3TC) High-level resistance 
abacavir (ABC) High-level resistance 
zidovudine (AZT) High-level resistance 
stavudine (D4T) High-level resistance 
didanosine (DDI) High-level resistance 
emtricitabine (FTC) High-level resistance 
tenofovir (TDF) Intermediate resistance 
 
Non-Nucleoside RTI 
efavirenz (EFV) Intermediate resistance 
etravirine (ETR) High-level resistance 
nevirapine (NVP) High-level resistance 
rilpivirine (RPV) High-level resistance 
 
Our drug resistance profile reported for this patient was carried out in May 2013, with 
Stanford version 6.2.0 that has been active from 29.05.2012 up to 05.06.2013. After this 
version, there was the version 6.3.0 up to 19.09.2013; and then until today the version 6.3.1 
(that I think you have used). This explains the slightly different profiles that we got.  
 
3) Please carefully check for typos in the paper.  For example, please change "...41-year-old 
men, was evaluated from 2007 to 2010 in Bangui, Central African 
Repubblic, where he performed..." to "...41-year-old man, was evaluated from 2007 to 2010 
in Bangui, Central African Republic, where he was tested with..." 
 We agree with the reviewer. 
 
4)  It is very highly unusual for a HIV-seronegative man (the paper says he repeatedly tested 
negative, with just one positive test: ELISA only, not western blot?? in 2007?) to harbor an 
X4 drug resistant virus.  Was the 2007 ELISA very strongly positive?  What was the reason 
for this man being repeatedly tested?  What is his risk for infection?   
The transmission of resistant variants is well documented: for this reason all guidelines 
suggest to test patients before starting therapy to identify drug resistance transmission. On 
CXCR4 variants transmission there are not confirmed data yet, but, in contrast with previous 
studies, recent reports suggest that CXCR4 viruses are likely to be transmitted as well 
(reviewed in: C. Hedskog et al.; Transmission of the X4 Phenotype of HIV-1: Is There 
Evidence Against the ‘‘Random Transmission’’ Hypothesis?; JID 2012, 205:163-165). 
In 2007, our patient was tested only for HIV-1 Ab Elisa in Bangui, Central African 
Republic, whereby we have only the qualitative data (positive / negative), that is positive 
according to the Abbott Elisa test. We do not have a clear explanation for the repetition of 
tests, we can only say that both tests resulted negative in 2009 and 2010. His risk factors for 
HIV-1 infection were blood transfusions and unprotected heterosexual intercourses.  
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5) In the paragraph pointed out in comment 3 above, the paper says the patient hod only one 
positive test, in 2007, never another. But on the next page the paper says that the patient has 
a positive ELISA and western blot in 2012.  Combining the statements into one paragraph 
explaining that the patient had negative results in Bangui but positive tests in Milan might 
reduce confusion. We agree with the reviewer. 
 
6) The authors should use the "Subtype Reference Alignment" with nonrecombinants plus 
CRF11_cpx sequences.  The paper states that the complete genome alignment was used, but 
there are hundreds of complete genomes in the LANL HIV genome alignment, and a very 
few have been carefully chosen for "references". 
http://www.hiv.lanl.gov/content/sequence/NEWALIGN/align.html 
The phylogenetic tree is acceptable as it is, this paper is not primarily about the phylogeny, 
so just clarifying that the subtype reference alignment was used, should be sufficient. We 
agree with the reviewer. 
 
 
Best wishes, 
Pamela Tau and Stefano Rusconi 
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